These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 857026)

  • 1. A preliminary Pharmacokinetic study of dianhydrogalactitol (NSC-132313) disposition in the dog.
    Kimura T; Sternson LA; Stella VJ; Higuchi T
    J Natl Cancer Inst; 1977 May; 58(5):1311-4. PubMed ID: 857026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the distribution of dianhydrogalactitol into the central nervous system of the rat.
    Munger D; Sternson LA; Patton TF
    Cancer Treat Rep; 1978 Mar; 62(3):409-12. PubMed ID: 647698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uptake of labeled dianhydrogalactitol into human gliomas and nervous tissue.
    Eckhardt S; Csetényi J; Horváth IP; Kerpel-Fronius S; Számel I; Institóris L; Szlovik F; Pásztor E; Afra D
    Cancer Treat Rep; 1977 Aug; 61(5):841-7. PubMed ID: 890693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gas-chromatographic analysis for 1,2:5,6-dianhydrogalactitol, an anti-neoplastic agent, in plasma.
    Kimura T; Sternson LA; Higuchi T
    Clin Chem; 1976 Oct; 22(10):1639-43. PubMed ID: 975510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic study in a phase I trial with an alkylating agent, diacetyldianhydrogalactitol (DADAG).
    Erdélyi-Tóth V; Kerpel-Fronius S; Kanyár B; Eckhardt S
    Cancer Chemother Pharmacol; 1986; 16(3):257-63. PubMed ID: 3698167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and metabolism of dianhydrogalactitol DAG in patients: a comparison with the human disposition of dibromodulcitol DBD.
    Horváth IP; Csetényi J; Kerpel-Fronius S; Hegedüs L; Kanyár B; Eckhardt S
    Eur J Cancer Clin Oncol; 1986 Feb; 22(2):163-71. PubMed ID: 3699079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dianhydrogalactitol (NSC-132313): pharmacokinetics in normal and tumor-bearing rat brain and antitumor activity against three intracerebral rodent tumors.
    Levin VA; Freeman-Dove MA; Maroten CE
    J Natl Cancer Inst; 1976 Mar; 56(3):535-9. PubMed ID: 1255783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I evaluation of dianhydrogalactitol (NSC-132313).
    Haas CD; Stephens RL; Hollister M; Hoogstraten B
    Cancer Treat Rep; 1976 May; 60(5):611-4. PubMed ID: 991150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-performance liquid chromatographic analysis of dianhydrogalactitol in plasma by derivatization with sodium diethyldithiocarbamate.
    Munger D; Sternson LA; Repta AJ; Higuchi T
    J Chromatogr; 1977 Jul; 143(4):375-82. PubMed ID: 195971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell killing, kinetics, and recovery responses induced by 1,2:5,6-dianhydrogalactitol in dividing and nondividiing cells in vitro.
    Barranco SC; Flournoy DR
    J Natl Cancer Inst; 1977 Mar; 58(3):657-63. PubMed ID: 839561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical toxicologic evaluation of dianhydrogalactitol in dogs and monkeys.
    Folk RM; Pavkov KL; Thake DC
    Cancer Treat Rep; 1976 Oct; 60(10):1585-9. PubMed ID: 828520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of GGCC sequences of DNA with anticancer dianhydrogalacticol, detected by inhibition of restriction enzyme BspI.
    Financsek I; Guczi J; Hidvégi EJ
    Acta Biochim Biophys Acad Sci Hung; 1984; 19(3-4):177-84. PubMed ID: 6100663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic and antitumor effects of 1,2:5,6-dianhydrogalactitol (NSC-132313).
    Németh L; Institóris L; Somfai S; Gál F; Pályi I; Sugár J; Csuka O; Szentirmay Z; Kellner B
    Cancer Chemother Rep; 1972 Oct; 56(5):593-602. PubMed ID: 4652589
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase I trial of dianhydrogalactitol administered Iv in a weekly schedule.
    Vogel CL; Winton EF; Moore MR; Sohner S
    Cancer Treat Rep; 1976 Jul; 60(7):895-901. PubMed ID: 795538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Derivatives of 2,3-anhydro-DL-threitol, 2,3-anhydroerythritol, 2,3:4,5-dianhydrogalactitol, and 2,3:4,5-dianhydroallitol.
    Schneider G; Horváth T; Sohár P
    Carbohydr Res; 1977 Jun; 56(1):43-52. PubMed ID: 880588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanoma.
    Ahmann DL; Bisel HF; Edmonson JH; Hahn RG; O'Connell MJ; Frytak S
    Cancer Treat Rep; 1976 Nov; 60(11):1681-2. PubMed ID: 1021239
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II study of dianhydrogalactitol and ICRF-159 in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.
    Ahmann DL; O'Connell MJ; Bisel HF; Edmonson JH; Hahn RG; Frytak S
    Cancer Treat Rep; 1977; 61(1):81-2. PubMed ID: 324622
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative studies on the in vivo distribution pattern of dibromodulcitol and diepoxydulcitol.
    Pethes G
    Z Krebsforsch Klin Onkol Cancer Res Clin Oncol; 1973; 79(1):49-59. PubMed ID: 4281167
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I study of a five-day intermittent schedule for 1,2:5,6-dianhydrogalactitol (NSC-132313).
    Eagan RT; Moertel CG; Hahn RG; Schutt AJ
    J Natl Cancer Inst; 1976 Jan; 56(1):179-81. PubMed ID: 943554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and pharmacologic evaluation of split-dose intermittent therapy with dianhydrogalactitol.
    Eagan RT; Ames MM; Powis G; Kovach JS
    Cancer Treat Rep; 1982 Feb; 66(2):283-7. PubMed ID: 7034934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.